(Q33383758)

26 July 2017

title

Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study (English)

1 reference

multicenter clinical trial

26 July 2017

main subject

0 references

1 reference

1 reference

1 reference

F Kullmann

1

1 reference

26 July 2017

S Hollerbach

2

1 reference

26 July 2017

M M Dollinger

3

1 reference

26 July 2017

J Harder

4

1 reference

26 July 2017

M Fuchs

5

1 reference

26 July 2017

H Messmann

6

1 reference

26 July 2017

J Trojan

7

1 reference

26 July 2017

E Gäbele

8

1 reference

26 July 2017

A Hinke

9

1 reference

26 July 2017

C Hollerbach

10

1 reference

26 July 2017

E Endlicher

11

1 reference

26 July 2017

language of work or name

English

0 references

publication date

17 March 2009

1 reference

British Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

100

1 reference

26 July 2017

issue

7

1 reference

26 July 2017

page(s)

1032-1036

1 reference

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670003

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670003

28 July 2018

Cancer statistics, 2004

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670003

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670003

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670003

Optimal two-stage designs for phase II clinical trials

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670003

Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial

28 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604983

Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604983

Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670003

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670003

Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2670003

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19293797

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

[S3-Guidelines "Exocrine pancreatic cancer" 2007]

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19293797

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SJ.BJC.6604983

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference